GB202011130D0 - Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain - Google Patents

Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Info

Publication number
GB202011130D0
GB202011130D0 GBGB2011130.8A GB202011130A GB202011130D0 GB 202011130 D0 GB202011130 D0 GB 202011130D0 GB 202011130 A GB202011130 A GB 202011130A GB 202011130 D0 GB202011130 D0 GB 202011130D0
Authority
GB
United Kingdom
Prior art keywords
cannabidiol
brain
treatment
structural abnormalities
seizures associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2011130.8A
Other versions
GB2597287A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Research Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Ltd filed Critical GW Research Ltd
Priority to GB2011130.8A priority Critical patent/GB2597287A/en
Publication of GB202011130D0 publication Critical patent/GB202011130D0/en
Priority to PCT/EP2021/069836 priority patent/WO2022017927A1/en
Publication of GB2597287A publication Critical patent/GB2597287A/en
Pending legal-status Critical Current

Links

GB2011130.8A 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain Pending GB2597287A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2011130.8A GB2597287A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
PCT/EP2021/069836 WO2022017927A1 (en) 2020-07-20 2021-07-15 Use of cannabidiol in the treatment of seizures associated with perisylvian fissure syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2011130.8A GB2597287A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Publications (2)

Publication Number Publication Date
GB202011130D0 true GB202011130D0 (en) 2020-09-02
GB2597287A GB2597287A (en) 2022-01-26

Family

ID=72339063

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2011130.8A Pending GB2597287A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Country Status (2)

Country Link
GB (1) GB2597287A (en)
WO (1) WO2022017927A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8083124B1 (en) 1990-11-19 2011-12-27 General Electric Company Method for joining single crystal members and improved foil therefor
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531278A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
KR20200055067A (en) * 2017-09-19 2020-05-20 지네르바 파마슈티컬스, 인코포레이티드 Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults

Also Published As

Publication number Publication date
WO2022017927A1 (en) 2022-01-27
GB2597287A (en) 2022-01-26

Similar Documents

Publication Publication Date Title
GB202011161D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011175D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202110388D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011155D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011131D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011130D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011119D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011137D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011146D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011152D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011141D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011120D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202011143D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abbormalities of the brain
GB202011125D0 (en) Use of cannabidiol in the treatment of seizures associated wiht rare epilepsy syndromes related to structural abnormalities of the brain
GB202011140D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB202011150D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB202011123D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB202011159D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011174D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011134D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011127D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011156D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011158D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011124D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202011160D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities